Investigation of Differential Biology of Benign and Malignant Renal Masses Using Advanced Magnetic Resonance Imaging Techniques

ConditionKidney Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Cambridge

About this trial

The aim of this study is to develop techniques for non-invasive imaging of biology in participants with benign or malignant renal masses based on the novel scanning MRI techniques, including recently invented Hyperpolarised MRI, deuterium metabolic imaging and sodium MRI. This imaging study will: 1) acquire imaging data from human tissues following the injection of hyperpolarised 13C pyruvate and use 13C-MRI to monitor changes in the ratio of 13C-lactate to 13C-pyruvate; 2) acquire imaging data from human tissues using Sodium MRI or 3) acquire imaging data from human tissues following the oral consumable of deuterated glucose. Data acquired during this physiological study will be used to optimise future imaging protocols.In the UK and possibly in other countries, there are some patients with renal masses that are over treated or undergo unnecessary procedures such as surgery or biopsies, as they are thought to have a malignant tumour or a more aggressive tumour but after the procedure it is found that the mass was benign. The aim of this study is to determine whether one or all of these imaging techniques can differentiate between benign and malignant renal masses with the view to developing the techniques further and hopefully reducing the need for over treatment or unnecessary procedures in patients with benign masses.

Eligibility criteria

Qualifiers

Over 18 years old

Able to and provide written informed consent to participate

If female, postmenopausal or if women of child bearing potential (WOCBP) using a suitable contraception

If male, using a suitable contraceptive method for the duration of the study

Disqualifiers

Contraindication or inability to tolerate MRI

Pregnant or actively breast-feeding woman

If using an intrauterine contraceptive device (IUCD) as a method of contraception the device should be MRI safe at 3 T (researcher to confirm)

Clinically significant cardiac, pulmonary or neurological diseases as determined by the investigators

Trial design

Treatments tested in this trial

  • Hyperpolarised MRI
  • Sodium MRI
  • Deuterium metabolic imaging (DMI) MRI

Treatment groups

30 Participants
are divided into 3 treatment groups

Sponsors and collaborators